NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.
Recep DursunHatice Gül DursunAyşe Gül ZamaniMahmut Selman Yıldırımİlknur ÇınarPublished in: BioMed research international (2018)
Psoriasis is a common, chronic, and autoimmune skin disease. Factors that play a role in etiopathogenesis of psoriasis include internal factors such as genetic susceptibility and immunological factors and external factors such as stress, infection, trauma, drug, and environmental compounds. N-acetyltransferase 2 (NAT2) is a xenobiotic enzyme that is involved in the metabolism of drugs, environmental toxins, and carcinogens. In this study, we aimed to demonstrate whether the variations in the NAT2 gene lead to a predisposition to psoriasis by affecting the enzyme's ability to metabolize drugs and environmental components or not. Three polymorphisms (rs1799929, rs1799930, and rs1799931) in NAT2 gene were genotyped and compared by real-time PCR method in 260 psoriasis vulgaris patients and 200 healthy controls. There was no difference in the genotype distributions and allele frequencies of polymorphisms between psoriasis vulgaris patients and controls. When the effects of polymorphisms on the clinical features of the disease, such as onset age and severity, are assessed, it has been found that rs1799930 and rs1799929 are, respectively, associated with early onset age and severity of the disease. In conclusion, rs1799929, rs1799930, and rs1799931 polymorphisms of the NAT-2 gene do not appear to be a risk factor for the development of psoriasis. Conversely, they may have an effect on either more severe or early onset cases of the disease.
Keyphrases
- early onset
- end stage renal disease
- late onset
- atopic dermatitis
- genome wide
- ejection fraction
- copy number
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- multiple sclerosis
- gene expression
- drug induced
- emergency department
- patient reported outcomes
- dna methylation
- transcription factor
- electronic health record
- genome wide identification
- adverse drug
- patient reported